Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The STEP 1 trial for semaglutide showed that participants lost an average of 14.9 percent of body weight, but lean mass accounted for roughly 40 percent of the total weight lost
Ongoing Monitoring Regular virtual check-ins ensure progress, safety, and motivation
within 15 s of food leaving the mouth
GLP-1 receptor agonists bind to and activate GLP-1 receptors located throughout the body, particularly in pancreatic beta cells, the gastrointestinal tract, and the central nervous system
Step 4: Get Ongoing Support Stay connected with unlimited provider messaging, follow-up visits, and app tools to help you track progress
placebo These results represent strain-level evidence from factorial analysis, not a finished-product trial in semaglutide users
